Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25658608 | 0.87 | FABP7 (0.37) | FABP7FABP5KMT2A | |
| SCHEMBL25657668 | 0.87 | FABP5 (0.38) | FABP7FABP5KMT2AMDM2 | |
| SCHEMBL25658613 | 0.86 | FABP7 (0.36) | FABP7FABP5KMT2A | |
| SCHEMBL25658612 | 0.86 | FABP7 (0.36) | FABP7FABP5KMT2A | |
| SCHEMBL25657669 | 0.85 | FABP5 (0.38) | FABP7FABP5KMT2AMDM2 | |
| SCHEMBL24579138 | 0.72 | KMT2A (0.39) | FABP7FABP5KMT2A | |
| SCHEMBL800127 | 0.71 | KMT2A (0.50) | FABP7FABP5KMT2A | |
| SCHEMBL2384012 | 0.71 | KMT2A (0.50) | FABP7FABP5KMT2A | |
| SCHEMBL119535 | 0.71 | KMT2A (0.50) | FABP7FABP5KMT2A | |
| SCHEMBL30055254 | 0.71 | KMT2A (0.50) | FABP7FABP5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FABP7 4602/4885FABP5 4094/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.